Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

cinod's efficacy and achieves target product profile

In 2008, NicOx successfully completed the phase 3 clinical program for naproxcinod in patients with OA of the knee (the 301 and 302 studies) and hip (the 303 study), with all three studies achieving highly statistically significant results on all three co-primary efficacy endpoints (the WOMAC(TM) pain subscale, WOMAC(TM) function subscale and subject's overall rating of disease status), as well as good overall safety and tolerability.

    - In July, the top-line results of the 52-week safety extension of the
      301 study were reported, which revealed no unexpected safety findings
      and showed a good overall long term safety for both doses of
      naproxcinod.

    - The 302 study reported top-line results in 1020 knee-OA
      patients in September 2008. In addition to meeting the three co-primary
      endpoints at 13 weeks (p<0.001), both doses of naproxcinod (750 mg and
      375 bid) were statistically non-inferior to naproxen 500 mg bid at 26
      weeks, in terms of the mean change from baseline in the WOMAC(TM) pain
      and function subscales.

    - Top-line results from the 303 study in 810 patients with OA
      of the hip were reported in November. Naproxcinod 750 mg bid met all
      three co-primary efficacy endpoints with high statistical significance
      (p<0.001).

During 2008, NicOx successfully completed an extensive database describing naproxcinod's blood pressure profile in more than 3,000 patients, using Office Blood Pressure Measurements (OBPM) and Ambulatory Blood Pressure Monitoring (ABPM).

Naproxcinod shows positive blood pressure results in phase 3 pooled analysis

In December 2008, NicOx announced the top-line results of the pooled blood pressure analysis from the phase 3 program (304). OBPM measurements were taken in a rigorous and standardized manner in each of the pha
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 ... the Adult Stem Cell Technology Center, LLC ( ASCTC ... appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the ... gave the address at the 4th World Congress on ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ... negative is the housing market remaining soft. , This solid ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... Azur Pharma Limited ("Azur,Pharma") today announced that ... Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R),(carbidopa-levodopa orally ... Fluxid(TM) (famotidine orally,disintegrating tablets) from UCB (Euronext: ... Niravam, Parcopa and Kemstro ...
... The readers of The IN VIVO Blog , which ... device industries, have selected a Deal of the Year ... with Takeda Pharmaceuticals .More than 2,500 reader votes were cast ... start to finish among the 13 nominees selected by The ...
... (Nasdaq: MATK ) announced today that it will ... conference. The conference is being held January 14-15, 2009 ... Dana Point, California. Peter L. Buzy, Chief Financial Officer, ... 14, 2009 at 1:25 PM PT.A live audio webcast of ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of Medicine have just developed an advanced imaging technique ... or white blood cells. Microdomains are restricted areas on ... signaling molecules accumulate during cell activation. Using digital multi-channel ... subsets and their forming microdomains in the vascular system ...
... single-walled carbon nanotubes (SWCNTs) shorter than about 200 nanometers ... pose an increased risk to health, according to scientists ... The results of their laboratory studies appear in an ... uses ranging from electronic displays to fuel cells to ...
... of Michigan analytical chemist Kristina Hakansson sets the stage ... growing body of evidence points to assemblies of sugars ... as accomplices in the growth and spread of tumors. ... traditional analytical methods have not been sufficient. , ...
Cached Biology News:New imaging technique tracks traffic patterns of white blood cells 2Cells selectively absorb short nanotubes 2A sweet step toward new cancer therapies 2
Rab1A...
Request Info...
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: